Showing results (141-150 of 295) with videos related to

Sort By:
Pageof 30
Clinical Genitourinary Cancer|March 26, 2022
Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targetsCoralea Kappel, Di Maria Jiang, Bryan Wong, et al.
European Journal of Human Genetics : EJHG|July 18, 2013
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer careFiona A Miller, Robin Z Hayeems, Jessica P Bytautas, et al.
Cancer Research|July 13, 2014
Enhancing reproducibility in cancer drug screening: how do we move forward?Christos Hatzis, Philippe L Bedard, Nicolai J Birkbak, et al.
F1000Research|December 10, 2020
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometryMilena Music, Marco Iafolla, Antoninus Soosaipillai, et al.
Oncotarget|June 2, 2018
Lung cancer in never smokers from the Princess Margaret Cancer CentreGrzegorz J Korpanty, Suzanne Kamel-Reid, Melania Pintilie, et al.
BMC Cancer|January 30, 2025
Clinical integration of germline findings from a tumor testing precision medicine programMaria Carolina Sanabria-Salas, Nina C Anggala, Brittany Gillies, et al.
JCO Precision Oncology|March 14, 2024
Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data SetKenneth L Kehl, Jessica A Lavery, Samantha Brown, et al.
Clinical Colorectal Cancer|August 21, 2021
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal CancerKanan Alshammari, Kyaw L Aung, Tong Zhang, et al.
British Journal of Cancer|July 7, 2023
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse eventsHelena J Janse van Rensburg, Zhihui Liu, Geoffrey A Watson, et al.
Endocrine-Related Cancer|October 11, 2011
Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancerPhilippe L Bedard, Sandeep K Singhal, Michail Ignatiadis, et al.
Pageof 30